Vocxi Health has developed MyBreathPrint®, a noninvasive system that utilizes a patented array of sensors to detect volatile organic compounds in exhaled breath, providing immediate disease analysis within one minute. This technology addresses the need for early disease detection, enabling patients to receive accurate health status assessments without the discomfort of needles or radiation.
Funding
$6.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for early disease detection often involve invasive procedures like needles or exposure to radiation, causing discomfort and potential risks for patients. Traditional diagnostic processes can also be time-consuming, delaying the availability of results and potentially hindering timely intervention.
Solution
Vocxi Health's MyBreathPrint® system offers a non-invasive solution for early disease detection through breath analysis. The system uses a patented array of sensors to detect volatile organic compounds (VOCs) in exhaled breath, providing a unique BreathPrint® for each individual. This BreathPrint® is then uploaded to a cloud-based platform where it is analyzed, and results are delivered to the physician. The technology aims to reduce the discomfort, risk, and waiting time associated with traditional diagnostic methods, enabling quicker and more accessible health status assessments.
Target Audience
The primary target audience includes physicians and healthcare providers seeking a rapid, non-invasive method for early disease detection, as well as patients at risk of or suspected of having conditions like lung cancer.
Features
- Non-invasive disease detection using exhaled breath
- Patented sensor array technology for VOC detection at parts per billion sensitivity
- Cloud-based platform for data analysis and reporting
- Results delivered to physicians in a matter of seconds
- Adaptable platform customizable to detect multiple diseases through machine learning
- Validated through extensive testing and human clinical studies